Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of ¹⁸F-DCFPyL PET/CT Restaging.

ABSTRACT:

Purpose

Our purpose was to investigate the effect of the addition of prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/CT) in patients with recurrent prostate cancer post-primary radiation therapy.

Methods and materials

A prospective, multi-institutional clinical trial evaluated 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (¹⁸F-DCFPyL) PET/CT restaging in 79 men with recurrent prostate cancer post-primary radiation therapy. We report actual patient management and compare this with proposed management both before and after PSMA-targeted PET/CT.

Results

Most patients (59%) had a major change in actual management compared with pre-PET/CT proposed managemen

SUBMITTER: Liu W 

PROVIDER: S-EPMC7820022 | biostudies-literature | 2021 Jan-Feb

REPOSITORIES: biostudies-literature